Kimmo Hatanpaa, M.D., Ph.D.

• Brain tumors
• Neurodegenerative diseases

 Featured Publications

Alterations in the RB Pathway With Inactivation of RB1 Characterize Glioblastomas With a Primitive Neuronal Component.

Chkheidze R, Raisanen J, Gagan J, Richardson TE, Pinho MC, Raj K, Achilleos M, Slepicka C, White CL, Evers BM, Patel TR, Malter JS, Hatanpaa KJ, J Neuropathol Exp Neurol 2021 Dec 80 12 1092-1098

Neurological infections in 2020: COVID-19 takes centre stage.

Fredrich S, Greenberg BM, Hatanpaa KJ, Lancet Neurol 2021 Jan 20 1 17-18

Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival.

Richardson TE, Patel S, Serrano J, Sathe AA, Daoud EV, Oliver D, Maher EA, Madrigales A, Mickey BE, Taxter T, Jour G, White CL, Raisanen JM, Xing C, Snuderl M, Hatanpaa KJ, J. Neuropathol. Exp. Neurol. 2019 Apr

BRAF mutation leading to central nervous system Rosai-Dorfman disease.

Richardson TE, Wachsmann M, Oliver D, Abedin Z, Ye D, Burns DK, Raisanen JM, Greenberg BM, Hatanpaa KJ Ann. Neurol. 2018 Jul

Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.

Richardson TE, Sathe AA, Kanchwala M, Jia G, Habib AA, Xiao G, Snuderl M, Xing C, Hatanpaa KJ J. Neuropathol. Exp. Neurol. 2018 May

Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis.

Daoud EV, Rajaram V, Cai C, Oberle RJ, Martin GR, Raisanen JM, White CL, Foong C, Mickey BE, Pan E, Hatanpaa KJ J. Neuropathol. Exp. Neurol. 2018 Feb

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.

Richardson TE, Snuderl M, Serrano J, Karajannis MA, Heguy A, Oliver D, Raisanen JM, Maher EA, Pan E, Barnett S, Cai C, Habib AA, Bachoo RM, Hatanpaa KJ J. Neurooncol. 2017 Apr

Clinical Outcome of Silent Subtype III Pituitary Adenomas Diagnosed by Immunohistochemistry.

Richardson TE, Mathis DA, Mickey BE, Raisanen JM, Burns DK, White CL, Hatanpaa KJ J. Neuropathol. Exp. Neurol. 2015 Dec 74 12 1170-7

Lymphomatosis Cerebri: A Diagnostic Challenge.

Hatanpaa KJ, Fuda F, Koduru P, Young K, Lega B, Chen W JAMA Neurol 2015 Jul

High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas.

Hatanpaa KJ, Hu T, Vemireddy V, Foong C, Raisanen JM, Oliver D, Hiemenz MC, Burns DK, White CL, Whitworth LA, Mickey B, Stegner M, Habib AA, Fink K, Maher EA, Bachoo RM J. Neurooncol. 2014 Mar 117 1 183-9

• American Association of Neuropathologists
  Moore Award for the Best Paper on Clinico-Pathological Correlation, honorable mention (2010)

• American Association of Neuropathologists
• Association for Molecular Pathology